Abstract
Relatively few therapy options exist for patients with prostate cancer that has become resistant to androgen-deprivation therapy and has metastasized to distant sites. Survival for such patients is poor with a median survival of ∼ 20 months from the time of initiation of standard docetaxel-based chemotherapy. Promising new treatments are needed and several are currently being evaluated, including those that target the hormonal-axis, such as abiraterone, chemotherapies, such as satraplatin and ixabepilone, combinations of chemotherapy with other agents, such as bevacizumab and calcitriol, as well as a variety of immunotherapeutic approaches. This review will highlight recent and current studies for many of the promising developments for advanced disease, as well as novel early stage approaches.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 13-22 |
| Number of pages | 10 |
| Journal | Expert Opinion on Investigational Drugs |
| Volume | 17 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2008 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Adrenal androgens
- Atrasentan
- Bevacizumab
- Calcitriol
- Castration-resistant prostate cancer
- Chemotherapy
- GVAX
- Immunotherapy
- Ipilimumab
- Ixabepilone
- Phase II
- Prostate cancer
- Satraplatin
- Sipuleucel-T
Fingerprint
Dive into the research topics of 'Novel therapeutic strategies in development for prostate cancer'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS